AIAISci
中文
clinical updateBiotech

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Clinical/translation signal: Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Occurred SourceClinicalTrials.govapprovedSourceClinicalTrials.gov

Factual summary

What happened

ClinicalTrials.gov registry update for Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

SourceClinicalTrials.gov

Why it matters

Clinical trial registry updates are translation signals, not commercialization claims by themselves.

SourceClinicalTrials.gov

Limitations

ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

SourceClinicalTrials.gov

Linked output

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomasclinical trial

People

No reviewed person relationship is attached to this event.

Organizations

Mayo Clinic

Topics

No reviewed topic relationship is attached to this event.

Problems

No reviewed problem relationship is attached to this event.

Relationship evidence

Timeline

  1. clinical updateRetifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
    SourceClinicalTrials.gov